Researchers at Duke University and the University of North Carolina at Chapel Hill will jointly form an Alzheimer’s Disease Research Center, one of 33 in the United States, with funding through the National Institutes of Health.
Read More
The acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between some of her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug.
Read More
Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. The Food and Drug Administration said it granted approval to the drug from Biogen based...
Read More
Based out of High Point, the firm is said to have a powerful pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases, including Alzheimer’s disease, diabetes and inflammation.
Read More
